Trials / Terminated
TerminatedNCT00849069
Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
An Observer-blind, Safety Study of GSK Biologicals' Haemophilus Influenzae and Streptococcus Pneumoniae Candidate Vaccine in Adults.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK2231395A | 3 doses intramuscular injections |
| BIOLOGICAL | TwinrixTM | 3 doses intramuscular injections |
Timeline
- Start date
- 2009-03-12
- Primary completion
- 2009-04-07
- Completion
- 2009-04-07
- First posted
- 2009-02-23
- Last updated
- 2017-10-31
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00849069. Inclusion in this directory is not an endorsement.